King Luther Capital Management Corp lowered its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 13.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,760 shares of the company’s stock after selling 11,935 shares during the period. King Luther Capital Management Corp owned 0.19% of Omnicell worth $3,765,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of OMCL. Janus Henderson Group PLC boosted its stake in Omnicell by 129.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after purchasing an additional 695,334 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Omnicell by 124.9% in the 2nd quarter. Principal Financial Group Inc. now owns 660,803 shares of the company’s stock worth $28,481,000 after acquiring an additional 367,019 shares during the period. First Light Asset Management LLC lifted its stake in shares of Omnicell by 108.0% in the 2nd quarter. First Light Asset Management LLC now owns 278,294 shares of the company’s stock worth $11,994,000 after acquiring an additional 144,471 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Omnicell by 70.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 347,914 shares of the company’s stock worth $14,995,000 after acquiring an additional 143,474 shares during the period. Finally, Rice Hall James & Associates LLC lifted its stake in shares of Omnicell by 47.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 434,422 shares of the company’s stock worth $18,724,000 after acquiring an additional 139,069 shares during the period. Hedge funds and other institutional investors own 99.84% of the company’s stock.
Shares of Omnicell, Inc. (NASDAQ:OMCL) opened at $51.00 on Thursday. Omnicell, Inc. has a 52 week low of $31.85 and a 52 week high of $55.40. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.42 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The firm had revenue of $186.78 million during the quarter, compared to analysts’ expectations of $192.45 million. During the same quarter last year, the business earned $0.40 earnings per share. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. equities research analysts expect that Omnicell, Inc. will post 0.12 EPS for the current fiscal year.
In related news, EVP Robin Gene Seim sold 9,780 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $48.97, for a total value of $478,926.60. Following the completion of the sale, the executive vice president now owns 55,896 shares in the company, valued at $2,737,227.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter J. Kuipers sold 3,532 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $50.96, for a total transaction of $179,990.72. Following the completion of the sale, the vice president now owns 40,714 shares of the company’s stock, valued at approximately $2,074,785.44. The disclosure for this sale can be found here. Insiders sold 38,944 shares of company stock valued at $1,889,592 in the last quarter. Company insiders own 3.77% of the company’s stock.
Several research firms have recently commented on OMCL. Cantor Fitzgerald restated a “buy” rating and issued a $60.00 target price on shares of Omnicell in a research note on Tuesday. Oppenheimer restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Tuesday. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 1st. Craig Hallum restated a “buy” rating and issued a $62.00 target price (up previously from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Finally, Benchmark raised their target price on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $55.14.
WARNING: “King Luther Capital Management Corp Sells 11,935 Shares of Omnicell, Inc. (OMCL)” was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thestockobserver.com/2017/12/07/king-luther-capital-management-corp-sells-11935-shares-of-omnicell-inc-omcl.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.